Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Background: There is limited data on the effectiveness of glucagon-like-peptide-1 receptor agonists (GLP1RA) in patients living with chronic kidney disease (CKD).
Methods: We conducted a population-based retrospective cohort study in Ontario, Canada, to examine the effect of new GLP1RA use on cardiovascular outcomes in comparison to a propensity-score weighted cohort of patients taking dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) in patients with CKD. The primary outcome of this study was major adverse cardiovascular outcome (MACE) defined as non-fatal myocardial infarction (MI), unstable angina (UA), non-fatal ischemic stroke or transient ischemic attack (TIA), coronary revascularization, or cardiovascular death. Secondary outcomes included the individual components of MACE, heart failure visits, peripheral vascular disease events, lower limb amputation, and all-cause mortality.
Results: We identified 24,576 new users of GLP1RA and 44,367 new users of DPP-4 inhibitors. Among GLP1RA users, 92% had type 2 diabetes mellitus and 40% (10,070) had CKD stages 3-5. The primary composite outcome of MACE occurred in 2,670 individuals with a 12% lower risk in GLP1RA users (HR 0.88; 95% CI 0.80 –0.97) in comparison to DPP-4 inhibitor users. Reduction in MACE was largely driven by a 28% reduction in cardiovascular death in GLP1RA users (HR 0.72; 95% CI 0.62 –0.85), while non-fatal MI (HR 0.90; 95% CI 0.73 –1.12), UA (HR: 0.87; 95% CI 0.55 –1.39), coronary revascularization (HR 1.00; 95 % CI 0.87 –1.14), nor non-fatal stroke or TIA (HR 0.98; 95 % CI 0.77 –1.25) differed significantly by drug exposure. GLP1RA initiation was associated with a reduction in peripheral vascular disease events (HR 0.85; 95% CI 0.75 –0.97), first episode of heart failure, non-cardiovascular mortality, and all-cause mortality. Furthermore, new GLP1RA use was associated with a lower risk of all-cause ER visits or hospitalizations (HR 0.90; 95% CI: 0.87 –0.94). Sensitivity analyses with alternate definitions of MACE, a non-active drug comparator. and accounting for drug discontinuation or switching were in keeping with the primary analysis. In pre-specified subgroup analyses, no heterogeneity was observed by CKD stage (p=0.74), degree of albuminuria (p=0.43), or SGLT2 inhibitor use (p=0.86).
Conclusions: In patients with CKD, GLP1RA use was associated with a reduction in major adverse cardiovascular events consistent with data in non-CKD populations.
